Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials

Cancer

Volumn 77, Issue 12, 1996, Pages 2503-2513

  Buzdar, Aman U ^a   Smith, Robert ^b   Vogel, Charles ^c   Bonomi, Philip ^d   Keller, Alan M ^e   Favis, Gregory ^f   Mulagha, Mary ^g   Cooper, Judy ^g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Baptist Medical Center   (United States)

^c Miami Beach FL   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e Cancer Care Associates   (United States)

^f HALIFAX MEDICAL CENTER   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

breast carcinoma; fadrozole HCL; hormonal therapy; megestrol acetate; postmenopausal

Indexed keywords

AROMATASE INHIBITOR; FADROZOLE; MEGESTROL ACETATE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPNEA; EDEMA; FEMALE; FLUID RETENTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; DOUBLE-BLIND METHOD; FADROZOLE; FEMALE; HUMANS; MEGESTROL; MENOPAUSE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0029940269     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W     Document Type: Article

References (23)

1. Wingo PA, Tong T, Bolden SCA. Cancer Statistics 1995. CA Cancer J Clin 1995;45:8-30.
2. Buzdar AU. Current status of endocrine treatment of carcinoma of the breast. Semin Surg Oncol 1990;6:77-82.
3. Lippman ME, Allegra JC. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980;46:2829.
4. Rubens RD, Hayward JL. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 1980;46:2922.
5. Manni A, Arafah B, Pearson OH. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980;46:2338.
6. Hortobagyi GN, Buzdar AU, Frye D, Yap H-Y, Fraschini G, Halverson HC, et al. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1985;5:321-6.
7. Willemse PH, van der Pleog E, Sleijfer DT, Tjabbes T, van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 1990;26:337-43.
8. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Creagan ET, Hahn RG, et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982;5:155-60.
9. Ross MB, Buzdar AU, Blumenschein GR, Cooper MR, Capizzi RT, Christian R, et al. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 1982;49:413-7.
10. Muss HB, Paschold EH, Black WR, Cooper MR, Capizzi RT, Christian R, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (PAO). Semin Oncol 1985;12:55-61.
11. Alexieva-Figusch J, van Gilse HA, Jop WCJ, Phoa CH, Wijst JB, Treurnlet RE, et al. Progestin therapy in advanced breast cancer: megestrol acetate - an evaluation of 160 treated cases. Cancer 1980;46:2369-72.
12. Blackledge GRP, Latief T, Mould JJ, Spooner D, Morrison M. Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment. Eur J Clin Oncol 1986; 22:1091-4.
13. Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A, et al. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 1979;43:2207-14.
14. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, et al. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 1981; 305:545-51.
15. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, et al. Aminoglutethimide induced hematologic toxicity: worldwide experience. Cancer Treat Rep 1985; 69(9):1003-4.
16. Santen RJ. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Res Treat 1981;1:183-202.
17. Smals AGH, Dony JMJ, Smals AE, Pieters GFFM, Hermus ARMM, Boers GHJ, et al. Aromatase inhibition by 1-testolactone does not relieve the gonatropin-induced late steroidogenic block in normal men. J Clin Endocrinol Metab 1985; 60:1127.
18. Cocconi G. First generation aromatase inhibitors - aminoglutethimide and testololactone. Breast Cancer Res Treat 1994;30(1):57-80.
19. Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, et al. Specificity of low dose fadrozole hydrochloride (CGS-16949A) as an aromatase inhibitor. J Clin Endocrinol Metab 1991;73:99-106.
20. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segalopf A, Rubens RD, et al. Assessment of response to therapy in advanced breast cancer. A project of the program on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977;39:1289-94.
21. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients. A concise QL-Index for use by physicians. J Chron Dis 1981;34:585-97.
22. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LH, Goldberg RM, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-7.
23. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-74.